CHEST Annual Meeting

These findings are from the WAYFINDER clinical trial and were presented at the CHEST 2025 Annual Meeting.

Megan Dulohery Scrodin, MD, highlights Mayo Clinic's innovative COPD care model, emphasizing multidisciplinary collaboration and AI tools for improved patient outcomes.

Experts discuss breakthroughs in respiratory virus vaccines.

Research reveals varying impacts of GLP-1 receptor agonists on asthma risk, urging careful medication selection for patients with diabetes and respiratory issues.

A digital therapeutic app enhances access to behavioral cough suppression therapy.

James Chalmers, MBChB, PhD, discusses the ASPEN trial's findings on brensocatib's impact on lung structure and function in bronchiectasis patients.

Megan Dulohery Scrodin, MD, discusses COPD management challenges and the need for accessible care and cost reduction.

Sara Assaf, MD, shares insights on selecting biologic therapies for severe asthma, including biomarkers, patient factors, and managing nonresponders effectively.

The FDA's approval of GLP-1 for obstructive sleep apnea enhances treatment options, emphasizing pharmacists' vital role in patient care and management.